Cargando…

Direct Comparison of the Efficacy and Safety of Oral Treatments with Oleylphosphocholine (OlPC) and Miltefosine in a Mouse Model of L. major Cutaneous Leishmaniasis

BACKGROUND: Cutaneous leishmaniasis (CL) represents a range of skin diseases caused by infection with Leishmania parasites and associated with tissue inflammation and skin ulceration. CL is clinically widespread in both the Old and New World but lacks treatments that are well tolerated, effective an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fortin, Anny, Caridha, Diana P., Leed, Susan, Ngundam, Franklyn, Sena, Jenell, Bosschaerts, Tom, Parriott, Sandi, Hickman, Mark R., Hudson, Thomas H., Grogl, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161350/ https://www.ncbi.nlm.nih.gov/pubmed/25210745 http://dx.doi.org/10.1371/journal.pntd.0003144

Ejemplares similares

Oleylphosphocholine (OlPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice
por: Sonzogni-Desautels, Karine, et al.
Publicado: (2015)

Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2017)

Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2023)

Drug Delivery by Tattooing to Treat Cutaneous Leishmaniasis
por: Shio, Marina Temi, et al.
Publicado: (2014)

Updating the modified Thompson test by using whole-body bioluminescence imaging to replace traditional efficacy testing in experimental models of murine malaria
por: Caridha, Diana, et al.
Publicado: (2019)

SUCCESSFUL TREATMENT OF MULTIFOCAL CUTANEOUS LEISHMANIASIS WITH MILTEFOSINE
por: Madke, Bhushan, et al.
Publicado: (2011)

Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis
por: Castro, María del Mar, et al.
Publicado: (2017)

Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box against Intracellular Leishmania major Amastigotes
por: Khraiwesh, Mozna, et al.
Publicado: (2016)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine
por: Dorlo, Thomas P. C., et al.
Publicado: (2011)

Glutamine supplementation improves the efficacy of miltefosine treatment for visceral leishmaniasis
por: Ferreira, Carolina, et al.
Publicado: (2020)

Post-kala-azar Dermal Leishmaniasis Developing in Miltefosine-Treated Visceral Leishmaniasis
por: Koley, Sankha, et al.
Publicado: (2013)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

No evidence for cardiotoxicity of miltefosine()
por: Dorlo, Thomas P.C.
Publicado: (2022)

Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management
por: Sundar, Shyam, et al.
Publicado: (2007)

Lingual Leishmaniasis Presenting to Maxillofacial Surgery in UK with Successful Treatment with Miltefosine
por: Kassam, K., et al.
Publicado: (2013)

Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India
por: Patra, Pradyumna, et al.
Publicado: (2012)

Efficacy and Safety of Miltefosine in Treatment of Post-Kala-Azar Dermal Leishmaniasis
por: Sundar, Shyam, et al.
Publicado: (2015)

Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India
por: Srivastava, Saumya, et al.
Publicado: (2017)

Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
por: Palić, Semra, et al.
Publicado: (2019)

Miltefosine for the treatment of cutaneous leishmaniasis—A pilot study from Ethiopia
por: van Henten, Saskia, et al.
Publicado: (2021)

Failure of Miltefosine Treatment for Visceral Leishmaniasis in Children and Men in South-East Asia
por: Ostyn, Bart, et al.
Publicado: (2014)

Proteinuria reduction after treatment with miltefosine and allopurinol in dogs naturally infected with leishmaniasis
por: Proverbio, Daniela, et al.
Publicado: (2016)

Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
por: dos Santos Nogueira, Fabio, et al.
Publicado: (2019)

1662. Pushing the Dose: Miltefosine Treatment for a Supersized American with Cutaneous Leishmaniasis
por: Aronson, Naomi E, et al.
Publicado: (2019)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis
por: Voak, Andrew A., et al.
Publicado: (2021)

A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis
por: Pal, Dipankar, et al.
Publicado: (2013)

Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients
por: OLLECH, Ayelet, et al.
Publicado: (2020)

Clinical and Laboratory Response of Domiciled Dogs with Visceral Leishmaniasis Treated with Miltefosine and Allopurinol
por: Vaz, Talita Pereira, et al.
Publicado: (2023)

Safety and Effectiveness of Miltefosine in Post–Kala-Azar Dermal Leishmaniasis: An Observational Study
por: Sundar, Shyam, et al.
Publicado: (2023)

No evidence for cardiotoxicity of miltefosine – Reply()
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)

Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol
por: Gonçalves, Gustavo, et al.
Publicado: (2021)

Resolution of Cutaneous Old World and New World Leishmaniasis after Oral Miltefosine Treatment
por: Tappe, Dennis, et al.
Publicado: (2010)

A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis
por: Carnielli, Juliana B.T., et al.
Publicado: (2018)

Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis()()
por: Barroso, Daniel Holanda, et al.
Publicado: (2021)

Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of Leishmania donovani Visceral Leishmaniasis
por: Melcon-Fernandez, Estela, et al.
Publicado: (2023)

Oral miltefosine for refractory Acanthamoeba keratitis
por: Hirabayashi, Kristin E., et al.
Publicado: (2019)

Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
por: Lu, Lu, et al.
Publicado: (2020)

Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition
por: Bulté, Dimitri, et al.
Publicado: (2021)

Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled Trial
por: Machado, Paulo R., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_52irsc3elpegcitro2p3cq4n94